-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
U.
S.
scientific instrumentation supplier Bruker has acquired Optimal Industrial automation and Technologies, a UK-based specialist in pharmaceutical and biopharmaceutical process analysis technology, pharmaceutical manufacturing automation and quality assurance software, and systems integration, the company said a few days ago
.
The acquisition strengthens Bruker's position as a key software and solutions provider for small molecule, biologics and new drug model pharmaceutical companies
Financial details of the acquisition were not disclosed
.
Optimal's 2022 revenue is expected to be approximately $10 million, and its revenue growth rate and operating margin are expected to increase in 2023 and beyond
High-quality biopharmaceutical tools and automation capabilities will enhance Bruker's innovation capabilities and make more differentiated high-value NMR, mass spectrometry, SPR, molecular spectroscopy and other instruments, complement biopharmaceutical drug discovery capabilities and develop new life science solutions solutions, as well as PAT analysis and QA solutions
.
These biopharmaceutical tools enable Bruker's global biopharmaceutical customers to bring effective and safe medicines to market faster
.
Optimal specializes in the automation and optimization of batch and continuous processes from R&D to manufacturing in the biopharmaceutical industry.
As a comprehensive PAT solutions provider, Optimal provides the development, testing, deployment and support of quality-focused pharmaceutical production systems